literature

HIV mutation literature information.

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

PMID: 32105319 2020 The Journal of antimicrobial chemotherapy

Table: K103N

Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.

PMID: 32102660 2020 BMC infectious diseases

Result: In this study, 40 out of 2034 (1.97%) treatment-naive CRF01_AE-infected patients had transmitted DRMs, with the common DRMs comprising K103 N, G190S, K101E, T215S, K65R, and K219Q.

Result: The NNRTI-associated DRMs detected at TF time point included G190S/C (66.7%), K101E/N/Q (52.4%), V179D/I/A/T/E (45.2%), Y181C (42.9%), K103R/N/S (42.9%), and V106 M (23.8%) (Table 1).

High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.

PMID: 32049783 2020 Medicine

Result: The predominant major NRTI mutation was M184I/V, while K103N was the predominant NNRTI mutation (Table 2).

Discussion: NNRTI associated mutations detected included V90I, K103N, Y181C, H221Y, K101H, G190A, V106A, F227L,

Discussion: K103N and V106A individually can reduce susceptibility of HIV-1 to Nevirapine and Efavirenz by as much as 50-fold, and together with other mutations found in this study, high-level resistance can be acquired.

HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.

PMID: 32045455 2020 PloS one

Abstract: Antiretroviral resistance was detected in 21.5% of 93 pol sequences analyzed, with the M184I/V and K103N mutations that confer high-level resistance to NRTI and NNRTI, respectively, being the most frequent mutations.

Abstract: However, the K103N mutant viruses were found only in the East.

Result: The K103N

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: K103N

Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.

PMID: 32006797 2020 Bioorganic chemistry

Abstract: Compound 51 displayed exceptionally potent activity against WT virus (EC50 = 6 nM) and several mutant strains (L100I, EC50 = 8 nM, K103N, EC50 = 6 nM, Y181C, EC50 = 26 nM, Y188L, EC50 = 122 nM, E138K, EC50 = 26 nM).

Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.

PMID: 32005262 2020 AIDS research and therapy

Abstract: While K103N (50.8%) and G190A/S/

Discussion: For NNRTI class, K103N mutation (53.8%) was indicated as the most prevalent mutation followed by G190A/S/E/G (30.2%) similar to a study done in sub-Saharan Africa that indicated K103N (38.7%) and G190A/S/E/G (21.8%) as the most prevalent.

Discussion: This was anticipated given the fact that Efavirenz is highly used as the preferred NNRTI in this region and mutations K103N, G190A are among the most common single mutations that confer high-level resistance to all the first-generation NNRTIs.

Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.

PMID: 32004936 2020 European journal of medicinal chemistry

Abstract: Especially, 10i (EC50 = 0.43 muM) was more active to the L100I/K103N double-mutant strain as compared to both NVP (EC50 = 0.76 muM) and EFV (EC50 = 1.08 muM).

Method: The complex structure was obtained from the Protein Data Bank (WT RT: 1TL1, Y181C RT: 1JLB, K103N-Y181C double-mutated RT: 5VQY, L100I-K103N double-mutated RT: 2ZE2).

Result: Among these, K103N, Y181C or Y188L, carried by RT, are the most prevalent mutants.

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.

PMID: 31976534 2020 The Journal of antimicrobial chemotherapy

Abstract: In comparison, the prevalence of the common NNRTI mutations V90I, K101E/P, K103N/S, E138A/G/K/Q/R/S, Y181C/I/V and G190A/E/S/Q were higher (8.9%, 7.9%, 28.6%, 12.6%, 14.2% and 8.9%, respectively).

Abstract: RESULTS: The frequencies of doravirine-associated resistance mutations (total dataset versus NNRTI-failing patients) were: V106A/M, 0.8% versus 2.6%; V108I, 3.3% versus 9.2%; Y188L, 1.2% versus 2.6%; G190S, 0.3% versus 2.1%; F227C/L/V

Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.

PMID: 31956856 2020 EClinicalMedicine

Result: 35,428 copies/mL, p = 0 0032), including those with single Y181C, M184V or G190A mutations, and those with multiple NNRTI/NRTI mutations, but not among those with single K103N mutations (Table 3).

Result: Among participants taking NVP-ART, those with a single K103N or multiple NNRTI/NRTI mutations had higher rates of virologic failure compared to those with no PDR mutations (Table 2).

Result: Among the 59 participants with PDR, NNRTI mutations (K103N, Y181C, G190A) were detected in all but one (98 3%) and <

Browser Board

Co-occurred Entities

Filtrator